| Dr Karan
Weight-loss outcomes depend on starting weight, dose, adherence, diet, physical activity, medical history, and individual biology
Renal benefits of SGLT 2 inhibitors and GLP-1 receptor agonists: evidence supporting a paradigm shift in the medical management of type 2 diabetes
Cost-effectiveness studies conducted in the UK, Portugal, Canada, and the United States consistently concluded that semaglutide is cost-effective relative to lifestyle management and other pharmacotherapies, including liraglutide ( The present analysis builds on this literature by providing country-specific evidence for Greece, where liraglutide remains the only reimbursed obesity pharmacotherapy and is restricted to adults with morbid obesity and established cardiovascular disease or sleep apnoea
Importantly, obesity is not simply a matter of personal choice or willpower, Dunsavage said